Patients should have tumor tissue assessed for the presence of a driver mutation, such as mutated epidermal growth factor receptor (EGFR) or the anaplastic lymphoma kinase (ALK) fusion oncogene (Kerr et al., 2014). The gene discussed is EGFR; the disease is neoplasm.